Publication and non-publication of clinical trials in PTSD: an overview by Suliman, Sharain et al.
RESEARCH Open Access
Publication and non-publication of clinical
trials in PTSD: an overview
Sharain Suliman1* , Leigh van den Heuvel1, Alexandra Suryapranata1, Jonathan I. Bisson2 and Soraya Seedat1
Abstract
Background: Although a large number of clinical trials on interventions demonstrating efficacy (or lack thereof) are
conducted annually, much of this evidence is not accessible to scientists and clinicians.
Objectives: We aimed to determine the publication rate of posttraumatic stress disorder (PTSD) trials that have
been registered in clinical trial registries, and the factors associated with publication.
Methods: Trials, completed on January 15, 2015, were identified via the US National Institutes of Health clinical
trials registry, the European Union Clinical Trials Register and the WHO International Clinical Trials Registry Platform.
A systematic search for publications (published by the end of March 2018) related to each of the registered trials
were then performed.
Results: Four hundred and thirty-eight of 1982 potentially eligible trials were included. Only 34% of interventional
trials were registered prior to initiation, 9% were registered within 2 months of starting and 20% after trial
completion. Of the 438 included trials, 72% had generated peer-reviewed publications, while an additional 7% had
disseminated results in some other form (such as on the trial database), 26 months after trial completion.
Randomisation of a trial was the only factor individually associated with publication, in logistic regression analysis (p <
0.001). Intervention type, university as sponsor and study registration prior to completion were factors that influenced
the time to publication, using Cox regression (p < 0.001).
Conclusions: This study underscores the importance of timely and accurate publication and dissemination of trial
results, in order to avoid the potential waste of resources and to ensure research integrity and patient safety. We
suggest that authors and journal editors adhere to conditions set out by the International Committee of Medical
Journal Editors and that more diligent data sharing is encouraged through prospective trial registration and trial
reporting websites.
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Background
Although over US$100 billion is invested in medical re-
search, each year reports suggest that less than 50% of
funded research is ever published in full [1–5]. There
are a number of ethical arguments proposed for why the
results of all studies, particularly those involving human
volunteers, should be published or reported [6–9].
Turner and colleagues (2013) note that these include the
need to increase the returns on public investment (i.e.
by the sharing of knowledge and practical advances),
increase transparency, prevent research duplication (and
wastage of time and resources), allow the public (includ-
ing participants who have given of their time to the
study) access to the research process and the results and
inform patient and public decision-making (i.e. through
sharing new knowledge and practical advances) [9].
Publication in a peer-reviewed journal is an important
form of research dissemination. It offers a record of a
study’s scientific contribution, provides evidence to clini-
cians to inform practice and supports policy makers in
decision-making. The scientific community, however,
has a poor track record of dissemination of clinical trial
results [7, 10]. Poor publication rates may be attributed
to a plethora of factors, with some authors struggling to
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publish data that may not meet the standards of journal
editors and readers [7]. Publication bias, leading to lower
publication rates for trials with negative or inconclusive
results, and delayed publication times are other reasons
why research is not published [11–13].
In order to avoid the potential damage that can result
from incomplete knowledge and ensure the integrity of re-
search, many organisations have established trial registries
as another means to share data. ClinicalTrials.gov was
launched on February 29, 2000, initially, with the main
aim of establishing a registry of clinical trials investigating
drugs for patients with serious or life-threatening diseases,
regulated by the Food and Drug Administration (FDA). In
2004, the International Committee of Medical Journal
Editors (ICMJE) released a statement that, as of July 2005,
journals would require registration with a public trial regis-
try, prior to enrolment, as a condition of publication [14].
In 2006, the World Health Organization (WHO) estab-
lished standards and rules for the registration of studies in
registries, and in 2007, launched the International Clinical
Trials Registry Platform (ICTRP), which brings together
data from all registries meeting their standards into a single
searchable portal [15]. Researchers are currently required
to register interventional trials while the registration of
observational studies is optional [16]. The Declaration of
Helsinki, since 2008, re-stipulates that research studies in-
volving human subjects must be registered in a publicly ac-
cessible database before recruitment of the first subject
and further states that researchers, authors, sponsors, edi-
tors and publishers all have ethical obligations with regard
to the publication and dissemination of the results of their
research [17]. Clinicaltrials.gov and the European Clinical
Trials Database (EudraCT) have each included a section
that permits investigators to submit their results, since
2008 and 2013, respectively.
Recent advances in reporting requirements include the
Department of Health and Human Services (HHS) final
rule, which clarifies and expands the requirements for
reporting results information [18]. This was made pub-
licly available on September 16, 2016. The NIH, concur-
rently, issued a complementary policy under which all
NIH-funded clinical trials are expected to submit regis-
tration and results’ information, whether or not the trials
are covered by the FDA Amendments Act requirements.
This NIH Final Rule (42 CFR Part 11) came into effect
on January 18, 2017, with compliance expected on April
18, 2017 [19]. Further, the American Psychological Asso-
ciation’s (APA’s) revised reporting standards for writing
journal articles were released. This calls for registration
of a study prior to its implementation and a summary of
results on completion [20].
We examined the publication of all registered and
completed posttraumatic stress disorder (PTSD)-related
intervention trials in the ICTRP and in two major trial
registries (ClinicalTrials.gov and EudraCT), in order to
determine the rate of and time to publication and factors
associated with publication. In order to be as inclusive
as possible, we included trials where individuals with
PTSD were included or where any PTSD-related out-
comes (e.g. diagnosis, severity, symptomatology) were
assessed. PTSD is a highly comorbid disorder and many
of the drug and psychological interventions investigated
in trials have trans-diagnostic application and utility.
In this paper, we address the following questions:
(i) What proportion of PTSD-related intervention
trials registered in ClinicalTrials.gov, EudraCT and
ICTRP go on to be published and what are the
characteristics of these studies?
(ii) What is the time to publication and what factors
pertinent to registration are associated with time to
publication?
We hypothesised the following:
(i) Proportion of and time to publication of PTSD-related
studies would be similar to other conditions/disciplines
and that individual factors related to study quality and
characteristics would influence publication rates and
times (we did not have pre-specified hypotheses as to
what these individual factors would be).
(ii) Publication rates of studies with positive (statistically
significant) outcomes would be higher than those
with null (not statistically significant) outcomes.
Outcomes were as follows:
(i) Proportion of completed intervention trials that go
on to be published.
(ii) Length of time between study completion and
publication.
(iii)Factors that contributed to publication.
Methods
This was a cross-sectional overview of registered and
subsequently published trials. Considering that this was
an overview that entailed pooled analysis of secondary
data, ethical approval was not sought. Two independent
researchers (SS1 and LvdH) selected studies through
each phase of selection. The responsible researchers
agreed on the search terms to use and on study selection
and exclusion criteria, as well as on data abstraction
(selection of data items extracted from each contributing
article) and data extraction. The search terms included all
applicable synonyms for PTSD, were compiled in accord-
ance with the instructions for each database and were
tested prior to implementation. The exact search terms
used were “PTSD OR posttraumatic stress disorder OR
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post-traumatic stress disorder OR posttraumatic stress
disorder.” In each of the registries and search platform, we
searched all fields and placed no limits on the searches.
Our search terms were broad as we aimed to identify all
possible PTSD-related studies. Studies were identified
via Clinicaltrials.gov (www.clinicaltrials.gov), EudraCT
(https://www.clinicaltrialsregister.eu/) and ICTRP (http://
apps.who.int/trialsearch/Default.aspx). We extracted data
on all studies and manually identified studies that were
closed or completed. The ICTRP is a search platform con-
taining trial registration data obtained from primary regis-
tries and partner registries internationally that meet the
WHO clinical registry standards. We selected these three
registries/platforms because they are the largest. Trials
registered since the inception of each registry were down-
loaded on January 15, 2015; therefore, the date range for
the NIH registry was on February 29, 2000, until January
15, 2015, for the EU register on May 1, 2004, until January
15, 2015, and for the WHO platform on May 1, 2007,
until January 15, 2015. Inclusion criteria were predefined.
Any PTSD-related study, with original quantitative data,
was included. Qualitative studies, reviews, case reports
and letters to the editor were excluded (although we did
not expect to find these other study types registered on
the trial registries as they do not clearly fall within the
purpose of trial registries, we did). After ongoing or termi-
nated trials, duplicates and studies not related to PTSD
were removed, and there were 438 records to review.
(Terminated trials were excluded as they are less likely to
publish results, and our main aim was to evaluate the pub-
lication of completed studies.) See Fig. 1. We obtained in-
dependent peer review and approval of the search strategy
and documentation by an information specialist who uti-
lises the PRESS methodology.
Information of interest pertaining to each trial was
systematically extracted from the databases by two re-
searchers (SS1 and LvdH) and reconciled. This included
the following:
1) Database registration (which database/platform,
when registered)
2) Study status (completed, terminated/withdrawn,
active)
3) For completed studies: type of study (interventional,
observational, study design); intervention type
(i.e. behavioural/ psychological, such as cognitive
behavioural therapy, narrative exposure therapy,
motivational interviewing, mindfulness-based
therapy; drug, device/procedure, such as transcranial
direct current stimulation, photobiomodulation,
biofeedback), study duration, number of arms,
control conditions, location, numbers planned vs
enrolled; participants (types, numbers in each arm);
time between end of trial and publication; study
sponsors as defined in the ICTRP1 (none,
pharmaceutical/industry, government,
non-commercial, hospital, university); date and phase
of study registered; study outcome2 (primary and
secondary outcomes); changes to trial information,
contact details of responsible party
4) Publication: in a journal or disseminated in
another form
Five investigators then searched for peer-reviewed
publications or any results disseminated for each indi-
vidual study that was registered (LvdH and SS1 con-
ducted the initial search and data extraction, which were
verified by AS; IE and SW updated the results which
were checked by SS1). For each registered trial, we
searched via PubMed, Scopus, Google Scholar and Goo-
gle using keywords listed (when available), trial titles, in-
vestigator names and trial registration codes to identify
matching publications and/or results. Any report of a
trial that had included results for PTSD as a primary or
secondary outcome or as a covariate or had sampled in-
dividuals with PTSD was included. We considered a trial
published if it appeared in a peer-reviewed journal
(whether or not we could obtain the full article). We
considered trial results disseminated if they appeared in
a peer-reviewed journal, in a trial registry, in a report
(e.g. media article, organisation website) or thesis. If
publications were not found, investigators of these com-
pleted trials were e-mailed to ask for study-related publi-
cations and results (71 e-mail addresses were obtained
via the registries and 96 via online searches; we were un-
able to obtain e-mail addresses for 27 investigators. Of
the 167 investigators who were e-mailed, 70 responded).
If the completion date of a trial was missing (5% of tri-
als), we used the publication date as a proxy when this
was available. This search was completed on March 21,
2018, which yielded a minimum of 26 months between
trial completion (according to the completion date listed
in the trial registries) and publication. We describe all
studies in the results, but given the small number of ob-
servational studies listed and the fact that registration
for these studies is voluntary (they are not required to
be registered), we excluded them from further analysis.
Publications and trial data were independently reviewed
by two investigators to determine whether (i) manuscripts
or reported results were in fact related to the trial listed in
the registry (as not all manuscripts/reports noted the trial
1Sponsor refers to the individual, organization, group or other legal
entity which takes responsibility for initiating, managing and/or
financing a study. The Primary Sponsor may or may not be the main
funder.
2Outcome or outcome measure is defined as measurements observed
or collected from those human subjects who are enrolled in a research
trial.
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registration number in the publication, it was not always
clear, so a second reviewer double-checked this), (ii)
PTSD-related findings were reported (e.g. some reports/
papers reported on other study findings, but omitted to
report findings related to PTSD—PTSD might have been
a secondary outcome in some of these), (iii) PTSD-related
outcomes were the primary or secondary outcomes mea-
sured, both or other (e.g. a condition or covariate) and (iv)
whether primary and secondary findings were positive
(statistically significant, p < 0.05), null (no statistically sig-
nificant finding, p ≥ 0.05) or mixed (both statistically sig-
nificant and no statistically significant findings in primary
and/or secondary outcomes). Where results were reported
in both a publication and another disseminated source
and these differed, the publication results were used.
Statistical analysis
We present descriptive statistics for all studies split ac-
cording to interventional and observational trials. As our
main outcomes of interest were related to interventional
trials, we examined univariate factors associated with the
publication of interventional trials and entered significant
variables into a logistic regression. The Kaplan-Meier
method [21] was used to estimate the time between
intervention trial completion and a paper related to that
trial being published in a journal while the Breslow statis-
tic [22] was used to determine significance. Significant
covariates were then entered into a Cox Regression [23] to
determine whether the time to publication was predicted
by significant covariates. Analyses were conducted in
SPSS, with two-tailed tests. p values of ≤ 0.05 were consid-
ered significant.
Results
Descriptive results of trials from the registry
All 438 trials were found on the ICTRP search platform,
although 53 (12%) were not initially identified via ICTRP
with the search terms used. Of these, 52 (12%) were
identified in ClinicaTrials.gov only and 1 (0.2%) on
EudraCT only. Furthermore, 322 (74%) trials were iden-
tified in both ICTRP and ClinicalTrials.gov, 2 (0.5%) in
ICTRP and EudraCT and 61 (14%) in ICTRP only. In
Fig. 1 Flow diagram of the selection process
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terms of registries of primary origin, 381 (87%) were regis-
tered in ClinicalTrial.gov; 21 (5%) on BioMed Central’s
International Standard Registered Clinical/soCial sTudy
Number (ISRCTN); 9 (2%) in the Australian New Zealand
Clinical Trials Registry (ANZCTR); 8 (2%) in the Iranian
Registry of Clinical Trials (IRCT), with 5 or less from
Japan Primary Registries Network (JPRN) (1%); Chinese
Clinical Trials Registry (ChiCTR) (< 1%); EudraCT (< 1%);
German Clinical Trials register (< 1%); Netherlands Trial
register (< 1%); and Clinical Trials Registry - India (CTRI)
(< 1%).
The majority of included trials, 380 (87%) were inter-
ventional and 58 (13%) were observational in design.
[See Table 1]. According to the data downloaded from
the trial registries, PTSD was the primary condition in
91% of studies, main outcomes were PTSD related in
69% of trials, and secondary outcomes were PTSD re-
lated in 34% of trials. Around two thirds (66%) of studies
were conducted in North America, followed by Europe
(15%), Asia (13%), Africa (2%), Australia (2%) and South
America (1%). Only 4.2% of studies were registered in
low- and middle-income countries (based on the Word
Bank categories).
Blinding status varied significantly (p < 0.001) accord-
ing to intervention type with drug trials more likely to
be double-blind (73%) than open-label (19%). Psycho-
logical intervention trials were more likely to be open-
label (43%) followed by single-blind (37%), and combined
drug and psychological intervention trials were more
likely to be double-blind (60%) than single-blind (28%).
Pharmaceutical companies and other industry accounted
for the smallest sponsorship contribution (8%). Industry/
pharmaceutical companies were more likely (p < 0.001) to
be a sponsor of drug trials (79%), followed by sponsorship
of trials of psychological interventions (17%) and combined
psychological and drug interventions (3%). Universities
were more likely (p = 0.001) to be sponsors of psycho-
logical intervention trials (74%), followed by drug (19%)
and combined psychological and drug trials (6%). Hospitals
were more likely (p = 0.024) to be a sponsor of psycho-
logical intervention trials (56%), followed by drug trials
(24%), trials of procedures/devices (12%) and combined
psychological and drug intervention trials (8%). Govern-
mental organisations were also more likely (p = 0.034) to
sponsor psychological intervention trials (71%), followed
by drug (17%), combined drug and psychological interven-
tion trials (7%) and studies of procedures/devices (5%).
There was no significant relationship between non-
commercial sponsorship and the type of intervention.
Entries into the database were changed over time, with
evidence that information entered was updated or chan-
ged at least once in 82% of the studies. Registration rates
increased after registration was made a requirement by
the ICJME—37% of trials were registered prior to
initiation in 2006 or later versus 20% in the preceding
years (p = 0.04).
Published and disseminated result outcomes
Of the trials that were registered, 317 (74%) yielded
traceable peer-reviewed publications, while another 32
(8%) studies had disseminated results in some other
form (e.g. on the trial registry, in a dissertation or pub-
lished report) (Table 2). Findings were obtained for 308
(81%) interventional trials. We were unable to obtain the
remaining papers that had been disseminated, and thus,
unable to extract the results.
Factors associated with publication of interventional trials
Whether a trial was randomised (p = 0.002), the type of
intervention studied (p = 0.010), whether a pharmaceut-
ical company/industry was involved in sponsoring the
trial (p = 0.005) and whether a contact email address was
provided in the registry (p = 0.021), were factors that
were significantly associated with a trial being published
in a journal (Table 3). These factors were subsequently
entered into a logistic regression.
The overall model was significant (χ2 (6) = 22.26,
p < 0.001), with a Nagelkerke R2 of 0.085, and predicted
75% of publications correctly. The only variable that was
individually associated with publication status was ran-
domisation (p = 0.007). Having pharmaceutical/industry
sponsorship (p = 0.073), provision of a contact email
(p = 0.088) and intervention type were not significant
(Table 4).
Factors associated with time to publication of
interventional trials
The Kaplan-Meier method [21] was used to estimate the
time between trial completion and a trial-related paper
being published (Table 5). The median time to journal
publication was 27.0 months (95% CI 24.0; 30.0). Factors
that influenced time to publication of interventional trials
were whether a control condition was used (p = 0.021),
whether the trial was randomised (p = 0.013), the inter-
vention type (p = 0.004), whether a university was involved
as a sponsor (p = 0.026), the number of treatment arms
(p = 0.034) and whether the study was registered in a trial
registry before it was completed (p = 0.040).
These significant factors were entered into a Cox
regression (Table 6). The overall model was significant
(χ2 (9) = 32.69, p < 0.001) with a 2 log-likelihood of 2271.
Variables influencing publication time were intervention
type—drug-only studies took significantly longer to pub-
lish than any other intervention study type; university
sponsorship was associated with faster publication time;
and trials that were registered in a database before being
completed were also associated with faster publication
times. Randomisation, number of treatment arms and
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Table 1 Descriptive data for interventional and observational trials listed in registries
Variable Total Interventional Observational
n = 438 n = 380 n = 58
Number enrolled, Mdn (IQR) 70 (36; 133) 62 (33; 120) 209 (78; 500)
Duration of study (months), Mdn (IQR) 29 (16; 45) 31 (16; 47) 26 (13; 36)
Gender, n (%)
Male only 35 (8) 30 (8) 5 (9)
Female only 54 (12) 49 (13) 5 (9)
Both 348 (80) 300 (79) 48 (83)
Age group
Adult 383 (87) 331 (87) 52 (89)
Child 37 (8) 33 (9) 4 (6)
Both 18 (4) 16 (4) 2 (3)
Any control condition used, n (%) (e.g. waitlist, placebo) 354 (81) 339 (89) 15 (26)
Comparator used 136 (31) 127 (33) 9 (16)
Randomisation, n (%) n/a
Randomised 326 (86)
Non-randomised 21 (6)
Single group 28 (7)
Unclear 5 (1)
Blinding n/a
Double blind 103 (27)
Single blind 108 (28)
Open label 132 (35)
Unclear 37 (10)
Intervention type, n (%) n/a
Drug 85 (22)
Behavioural 247 (65)
Drug and behavioural 25 (7)
Procedure/device 23 (6)
Number of study arms, n (%)
One 73 (17) 40 (11) 33 (57)
Two 294 (67) 278 (73) 16 (28)
Three to six 71 (16) 62 (16) 9 (16)
Actual vs planned enrolment, n (%)
More than planned 71 (16) 57 (15) 14 (24)
Less than planned 171 (43) 150 (37) 21 (36)
No difference 187 (39) 168 (44) 19 (33)
Status of main sponsor, n (%)
University 176 (40) 164 (43) 12 (21)
Hospital 93 (21) 76 (20) 17 (29)
Governmental organisation 114 (26) 90 (24) 24 (41)
Non-commercial (e.g. NGO) 47 (11) 44 (12) 3 (5)
Pharmaceutical/industry 8 (2) 6 (2) 2 (3)
Any secondary sponsors listed, n (%) 209 (48) 193 (51) 16 (28)
Any sponsor university 199 (45) 183 (48) 16 (28)
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having a control group were no longer statistically
significant.
Discussion
We conducted a review of trials related to PTSD in the
ICTRP platform and two of the largest trial registry da-
tabases with a view to determining factors that might in-
fluence publication. Of the 380 registered interventional
trials included, we found that at least 26 months after
trial completion, the peer-reviewed journal publication
rate was 74%. This increased to 82% when we included
trials that had published results in some other form (e.g.
in a trial registry or in a published report). This is better
than or equivalent to the rate reported for other disease
areas and is likely to further increase with time since
trial completion. In one study on vaccine trials, the
publication rate after 12 months was 12% and increased
to 73% at 48 months post-study completion [24]. An-
other study of randomised clinical trials registered with
ClinicalTrials.gov reported a publication rate of 71% at
60 months after study completion [25]. Time from the
close of a study until publication was approximately
2 years and 3 months. This is in line with findings from
other studies [26, 27], but may be longer given that
when the completion date of a trial was missing, we
used the publication date as a proxy.
It is concerning that even though registration prior to
enrolment is required by the ICMJE, and has been in-
cluded in the Declaration of Helsinki, only one third of
interventional trials were registered prior to initiation, a
further 9% within 2 months of starting and 20% after
trial completion. Furthermore, despite the rate of regis-
tration prior to trial initiation having increased over
time, the rate since 2006 is much lower than expected
(over 60% were registered after trial initiation), when
considering that the ICMJE instituted its requirement in
2005. A recent review of articles published in psychiatry
journals which require prospective trial registration found
that 34% were retrospectively registered and that only 33%
of studies were correctly prospectively registered [28]. An-
other study found that only 54% of recently published
antidepressant and cognitive behavioural therapy trials
were registered and only 25% were properly registered
[29]. Only 15% of RCTs published in clinical psychology
journals were registered prospectively and even fewer (1%)
were both prospectively and completely registered [30].
Similarly, the large number of trials with no documented
difference in the number of participants planned for
enrolment and the number actually enrolled is likely due
to studies that were registered retrospectively. As clinical
Table 1 Descriptive data for interventional and observational trials listed in registries (Continued)
Variable Total Interventional Observational
n = 438 n = 380 n = 58
Any sponsor hospital 106 (24) 89 (23) 17 (30)
Any sponsor governmental organisation 231 (53) 200 (53) 31 (54)
Any sponsor non-commercial 72 (17) 67 (18) 5 (9)
Any sponsor pharmaceutical/industry 34 (8) 29 (8) 5 (9)
Contact email provided, n (%) 188 (43) 172 (45) 16 (28)
Registered before 2006, n (%) 97 (22) 81 (21) 16 (28)
Study registered before started, n (%) 151 (35) 127 (34) 24 (42)
Study registered before completed, n (%) 336 (80) 291 (80) 45 (79)
More/less than planned was based on a difference of 10% or more and obtained from the trial registry. Any sponsor/secondary sponsors include university, hospital,
governmental or pharmaceutical/industry funding.
IQR interquartile range, Mdn median, NGO non-governmental irganization, n number; % percentage
*p < 0.05
Table 2 Publication data for (i) all studies and (ii) interventional trials
Variable Total Interventional
Results disseminated in any form, n (%) 349 (80) 313 (82)
Results found on registry, n (%) 103 (24) 96 (25)
Published in a journal, n (%) 317 (72) 281 (74)
Obtained results for the trial, n (%) 343 (78) 308 (81)
Are the results related to PTSD, n (%) 326 (95) 298 (97)
PTSD diagnosis/symptoms as an outcome, n (%)
Primary 170 (52) 160 (54)
Secondary 57 (18) 51 (17)
Both primary and secondary 58 (18) 55 (19)
Other (e.g. covariate, condition studied) 40 (12) 31 (10)
Primary outcome measure/s, n (%)
Positive 181 (59) 165 (59)
Null 75 (25) 67 (24)
Mixed 50 (16) 47 (17)
Secondary outcome measure/s, n (%)
Positive 144 (44) 111 (43)
Null 57 (20) 55 (21)
Mixed 98 (35) 92 (36)
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Table 3 Factors associated with publication of interventional trials
Variable Published Not published Test statistic p value
Randomised, n (%) 252 (90) 74 (78) χ2(1) = 9.15 < 0.002*
Blinding χ2(2) = 5.51 0.064
Double blind 78 (31) 25 (28)
Single blind 86 (34) 22 (24)
Open label 88 (35) 44 (48)
Intervention type, n (%) χ2(3) = 11.45 0.010*
Drug 52 (19) 33 (33)
Behavioural 191 (68) 56 (57)
Drug and behavioural 22 (8) 3 (3)
Procedure/device (e.g. TMS) 16 (6) 7 (7)
Any control condition used, n (%) (e.g. waitlist, TAU) 255 (91) 84 (85) χ2(1) = 2.65 0.104
Placebo used 68 (24) 27 (27) χ2(1) = 0.369 0.544
Comparator used 94 (34) 33 (33) χ2(1) = 0.00 0.983
Number of study arms, n (%) χ2(2) = 5.35 0.069
One 24 (9) 16 (16)
Two 213 (76) 65 (66)
Three to six 44 (16) 18 (18)
Status of the main sponsor, n (%) χ2(4) = 9.3 0.055
University 128 (46) 36 (36)
Hospital 59 (21) 17 (17)
Governmental organisation 57 (20) 33 (33)
Non-commercial (e.g. NGO) 34 (12) 10 (10)
Pharmaceutical/industry 3 (1) 3 (3)
Any secondary sponsor listed, n (%) 148 (53) 45 (46) χ2(1) = 1.53 0.217
Any sponsor university 141 (50) 42 (42) χ2(1) = 1.76 0.184
Any sponsor hospital 71 (25) 182 (18) χ2(1) = 2.049 0.152
Any sponsor governmental organisation 146 (52) 54 (55) χ2(1) = 0.20 0.657
Any sponsor non-commercial 53 (19) 14 (14) χ2(1) = 1.12 0.289
Any sponsor pharmaceutical/industry 15 (5) 14 (14) χ2(1) = 8.048 0.005*
Contact email provided, n (%) 137 (49) 35 (35) χ2(1) = 5.31 0.021*
Are the results related to PTSD, n (%) 269 (97) 29 (97) χ2(1) = 0.00 0.978
PTSD-related outcome/s, n (%) χ2(3) = 4.75 0.191
Primary 145 (54) 15 (54)
Secondary 47 (18) 4 (14)
Both primary and secondary 52 (19) 3 (11)
Other (e.g. covariate or condition studied) 25 (9) 6 (21)
Primary outcome measure/s, n (%) χ2(2) = 5.64 0.060
Positive 156 (59) 9 (56)
Null 60 (23) 7 (44)
Mixed 47 (18) 0 (0)
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trial registries are used by researchers, clinicians and the
public, it is important that they are accurate and up to
date. Our findings also highlight the dearth of trials regis-
tered in low- and middle-income countries. Studies from
these countries may be registered in trial databases not
included in this review, but as the ICTRP only includes
registries fulfilling their standards, these databases may
not meet current requirements.
Trial randomisation was the only factor associated
with peer-reviewed publication, when other factors were
accounted for. Although not all prior studies have found
that more rigorous trial designs (i.e. randomisation) are
associated with publication [13], our results indicate that
they could be. Although only six interventional trials
had primary pharmaceutical/industry sponsorship and
29 had some industry involvement, these trials trended
towards a lower likelihood of publication. Given that the
industry provided sponsorship for 79% of drug-only tri-
als, this finding suggests that sponsorship may influence
publication with journals/industry setting stricter criteria
for drug trials. Provision of a contact e-mail and inter-
vention type was not significant when these other vari-
ables were accounted for. Whether results were positive
or null was also not significantly associated with publica-
tion status. This finding, however, does need to be
interpreted with caution as it is likely influenced by the
number of unpublished trials for which we were unable
to obtain any data.
With regard to the time to publication of interven-
tional trials, trials of drug interventions alone were likely
to be published later than those of drug and psycho-
logical interventions, psychological interventions alone
and those assessing a procedure or device. Again, this
may be because journals and/or authors have stricter
publication requirements for drug trials. Nonetheless,
this is concerning given the potentially serious and far-
reaching implications of a lack of up-to-date evidence
on the provision of effective pharmacotherapies to
inform treatment guidelines. Trials with a university
involved as a sponsor were likely to be published sooner
than those without. This may be due to universities pro-
viding funding to their own academics, who are often
rewarded based on their publication outputs. Trials reg-
istered in a trial database before trial completion were
also likely to be published sooner than those regis-
tered after completion. This may indicate that authors
are likely to consider and prepare their data for publi-
cation prior to trial completion and that those who
register their trials before trial closeout intend to
publish their data. Trial randomisation was no longer
statistically significant when these other factors were
accounted for.
Table 3 Factors associated with publication of interventional trials (Continued)
Variable Published Not published Test statistic p value
Secondary outcome measure/s, n (%) χ2(2) = 1. 65 0.439
Positive 109 (44) 2 (25)
Null 52 (21) 3 (38)
Mixed 89 (36) 3 (38)
Study registered before started, n (%) 92 (33) 35 (35) χ2(1) = 1.17 0.683
Study registered before completed, n (%) 207 (78) 84 (86) χ2(1) = 2.42 0.120
*p < 0.05
Table 4 Logistic regression of factors influencing publication
Variable B Wald χ2 Significance Odds ratio (95% CI)
Constant − 0.11 0.07 0.790
Randomised 0.87 7.20 0.007* 2.40 (1.27; 4.54)
Intervention type
Druga 3.21 0.360
Behavioural 0.41 1.73 0.189 1.50 (0.82; 2.76)
Procedure/device 0.31 0.30 0.584 1.36 (0.45; 4.12)
Drug and behavioural 1.07 2.52 0.112 2.92 (0.78; 10.93)
Any sponsor pharmaceutical/industry 0.79 3.21 0.073 0.45 (0.19; 1.08)
Contact email provided 0.43 2.92 0.088 1.54 (0.94; 2.53)
Model χ2(6) = 22.26 (p < 0.001*)
Nagelkerke R2 = 0.085
*Significance set at p < 0.05
aDrug intervention was the type of intervention against which other interventions were analysed
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Some of the authors we contacted provided reasons
for not having published their work. These included re-
sults not worth publishing, small sample size, null find-
ings and publication rejected by journals submitted to.
Other reports have noted similar motivations for non-
publication. Publication bias and lower publication rates
for studies with negative or inconclusive results include




Overall 27 (24; 30)
Randomised χ2(1) = 6.15 0.013*
Yes 26 (23; 29)
No 39 (32; 46)
Blinding χ2(2) = 2.54 0.281
Double blind 30 (24; 36)
Single blind 24 (21; 27)
Open label 23 (26; 40)
Intervention type χ2(3) = 13.33 0.004*
Drug 39 (28; 50)




Drug and behavioural 20 (20; 34)
Any control condition
used (e.g. waitlist, TAU)
χ2(1) = 5.35 0.021*
Yes 26 (23; 29)
No 39 (33; 45)
Placebo used χ2(1) = 0.65 0.422
Yes 30 (24; 37)
No 27 (24; 30)
Comparator used χ2(1) = 0.97 0.324
Yes 27 (23; 31)
No 29 (24; 34)
Number of study arms χ2(2) = 6.75 0.034*
One 44 (37; 52)
Two 25 (22; 28)
Three to six 30 (20; 40)
Any sponsor university χ2(1) = 4.99 0.026*
Yes 24 (20; 28)
No 32 (26; 38)
Any sponsor hospital χ2(1) = 0.08 0.776
Yes 29 (21; 37)
No 27 (24; 30)
Any sponsor governmental
organisation
χ2(1) = 0.450 0.502
Yes 28 (24; 32)




χ2(1) = 2.896 0.086
Yes 40 (0; 83)
No 27 (24; 31)






χ2(1) = 0.90 0.344
Yes 34 (23; 45)
No 27 (24; 30)
Contact email provided χ2(1) = 0.87 0.352
Yes 26 (23; 29)
No 29 (24; 34)
Are the results related
to PTSD
χ2(1) = 0.26 0.613
Yes 27 (23; 31)
No 39 (1; 77)
PTSD-related outcome χ2(3) = 1.80 0.615
Primary 31 (22; 40)









χ2(2) = 2.32 0.115
Positive 26 (23; 29)
Null 31 (25; 37)
Mixed 23 (14; 32)
Secondary outcome
measure/s
χ2(2) = 1.50 0.473
Positive 25 (21; 29)
Null 29 (22; 36)
Mixed 24 (20; 28)
Registered before 2006 χ2(1) = 0.32 0.573
Yes 31 (24; 39)
No 27 (24; 30)
Study registered before
started
χ2(1) = 1.07 0.302
Yes 27 (23; 31)
No 28 (24; 32)
Study registered
before completed
χ2(1) = 4.22 0.040*
Yes 28 (24; 32)
No 35 (26; 44)
*Significance set at p < 0.05
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the high standards of journal editors and the desire for
positive results [7, 9, 11]. It has, however, been pointed
out that the bias towards positive findings may come
from the authors themselves, rather than journal editors
and reviewers.
The strengths of this study are that it considered a
large number of trials that encompassed a variety of re-
search methodologies and were registered across a num-
ber of databases. To our knowledge, this is the first to
do this in the field of psychiatry and PTSD. Despite our
focus on PTSD-related trials, our results support the re-
ports of publication bias in other fields [24, 29]. It is,
however, important to recognise that there have been
major developments in trial reporting regulations and
guidelines in recent years (42 CFR Part 11, The Final
Rule, APA’s revised JARS guidelines). Thus, trials con-
ducted prior to these may be unrepresentative of current
registration and reporting practices. Nonetheless, our
findings support these new registration and reporting re-
quirements and indicate the need for mechanisms (i.e.
policies to support registration and reporting with penal-
ties for investigators who do not follow standards for
clinical research [31]) that ensure these regulations are
adhered to, as we have demonstrated that since the
ICMJE regulations many trials were still only registered
after completion.
The following limitations should also be noted: (i) in-
correct, inconsistent and incomplete information listed
in the trial registries. For example, we found that infor-
mation was not updated regularly, information in one
section of the registry did not always align with others
and trials that appeared on the list of “complete” studies
were at times still listed as “active.” This may also imply
that we may have missed trials that were in fact
completed, but were not updated as such on the system.
This has been a drawback since the inception of the
registries [32]. There may also be some misclassification
of hospital and university sponsors. We based this on
the name of the sponsor as entered in the trial registra-
tion database. In some instances, university hospitals
may be the primary sponsor but the university may, in
fact, be listed as the sponsor. We performed a post hoc
analysis to assess whether the effect of university spon-
sorship on time to publication was independent of hos-
pital sponsorship by adding hospital sponsorship to the
model and university sponsorship remained significantly
associated with time to publication, whereas hospital
sponsorship was not; (ii) although we made every effort
to locate published reports—peer-reviewed and other,
we may not have traced all, as publications were not al-
ways linked to trial registration numbers and not all
study contacts listed responded; (iii) we included various
study types, not only intervention trials in our initial
analyses. Given that only intervention trials are required
to be listed on these registries, we opted to exclude the
observational studies from further analysis. This, how-
ever, constituted only a small percentage of studies; (iv)
similarly, there were only a small number of trials
sponsored by industry, which warrants care in the inter-
pretation of the related findings; (v) we attempted to re-
trieve publications after a minimum of 26 months post-
completion. It is possible that our publication rate would
have increased had we used a longer post-completion
timeframe; (vi) although the search strategies were the
same across databases/search portals, not all the studies
were identified in ICTRP. This may be related to differ-
ences in search algorithms; (vii) these results may not be
generalizable to all trials. For example, previous studies
Table 6 Cox regression of factors involved in publication time
Variable B Wald χ2 Significance Relative risk (95% CI)
Randomised − 0.21 0.20 0. 653 0.82 (0.33; 1.99)
Treatment armsa 1.87 0.392
2 arms 0.55 0.87 0.351 1.74 (0.54; 5.56)
3–6 arms 0.36 0.34 0.562 1.43 (0.43; 4.73)
Any control used 0.095 0.07 0.797 1.10 (0.53; 2.27)
Intervention typeb 18.64 < 0.001*
Behavioural 0.51 8.65 0.003* 1.67 (1.19; 2.34)
Drug and behavioural 1.16 16.79 < 0.001* 3.20 (1.84; 5. 58)
Procedure/device 0.74 5.54 0.019* 2.09 (1.13; 3.87)
Any sponsor, university 0.26 3.88 0.049* 1.30 (1.00; 1.70)
Registered before completed 0.33 4.10 0.043* 1.40 (1.01; 1.93)
Model χ2(9) = 32.69 (p < 0.001*)
− 2 log-likelihood = 2271
*Significance set at p < 0.05
aOne arm was the number of arms against which other arms were analysed
bDrug intervention was the type of intervention against which other interventions were analysed
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suggest that the publication rate for registered trials is
higher than for other trials [33]. Similarly, registered tri-
als might differ from trials initially published as abstracts
(e.g. Scherer et al., 2018) or trials identified through In-
ternal Review Boards (e.g. Chan et al., 2004) [5, 34]. Fur-
thermore, registered trials may differ systematically from
unregistered trials, confounding interpretation of factors
associated with journal publication. Drugs and devices, for
instance, are FDA-regulated products and, as such, these
trials are much more likely to be registered and also more
likely to be reported in biomedical journals (which are
often ICMJE members and have registration require-
ments). Trials of non-regulated products, on the other
hand, are more likely to be reported in psychology and al-
lied health journals (which are not ICMJE members and
do not have registration requirements). This is illustrated
by a study that reviewed the registration of clinical trials in
clinical psychology journals, which found that most clinical
trials in psychology journals (with the exception of regis-
tered trials in clinical psychology) were not registered [30].
In sum, 74% of trials were published in peer-reviewed
journals and a further 8% had published results in some
other form 26 months after trial completion; publication
time from trial completion was approximately 2 years
and 3 months; despite ICMJE guidelines, a little over
one third of interventional trials were registered prior to
initiation; and few trials were registered in low- and
middle-income countries. Randomised trials were more
likely to be published and those with a contact e-mail
and no pharmaceutical sponsorship were not significant
when other variables were accounted for; null findings
were not associated with publication status. Trials spon-
sored by a university and those registered in a trial data-
base before trial completion were likely to be published
sooner than those registered after completion, while
drug-only trials took longer to publish.
Conclusion
By not sharing knowledge gained from these trials, re-
searchers waste valuable research funds, slow down ad-
vancement in the field, put patients and study participants
at risk of potentially ineffective or even harmful interven-
tions and distort the evidence base [11, 13]. In order to
safeguard research integrity, we therefore support the call
to encourage and make mandatory other methods of data
sharing, for example via prospective trial registration and
reporting websites such as those that we examined. Fur-
thermore, given that the utility of information on registries
is dependent on the quality of the information entered by
investigators, the large amount of inconsistent or missing
information we found on the databases indicates that
greater vigilance is required to improve the reliability and
accuracy of reporting. Recent initiatives in trial reporting
regulations are a step towards this.
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